Solventum, an American healthcare company spun off from 3M in 2024, has completed the sale of its purification and filtration business to Thermo Fisher Scientific for approximately USD 4 billion in cash, subject to customary adjustments, effective 1 September 2025.
The divested business is a leading global provider of purification and filtration technologies used in the production of biologics, as well as in medical technologies and industrial applications. It operates worldwide, with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.
Paksoy is pleased to announce that a team led by partner Stéphanie Beghe Sönmez and associates Meriç Saçak Albaş and Cansın Taner acted as Turkish counsel to Solventum, alongside Cleary Gottlieb Steen & Hamilton, which served as global counsel on this multijurisdictional transaction.
Share
Related persons
You can contact us for detailed information.


Legal Information
This briefing is for information purposes; it is not legal advice. If you have questions, please call us. All rights reserved.
You May Be Interested In
7 January 2026
Paksoy advises Sanofi on the sale of a majority stake in its Lüleburgaz manufacturing facility
Paksoy advises Sanofi on the sale of a majority stake in its Lüleburgaz manufacturing facility.
5 January 2026
We are pleased to announce the promotion of Sabri Kaya to Counsel, effective as of 1 January 2026
We extend our congratulations to Sabri Kaya on his well-deserved promotion to Counsel.
5 January 2026
We are pleased to announce the promotion of Doğuhan Uygun and Zekican Samlı to Partner, effective as of 1 January 2026
We extend our congratulations to Doğuhan Uygun and Zekican Samlı on their well-deserved promotion to Partner.
29 December 2025
Paksoy advised GAMA Enerji on the sale of İç Anadolu Natural Gas Combined Power Plant to SOCAR
Paksoy advised GAMA Enerji on the sale of İç Anadolu Natural Gas Combined Power Plant to SOCAR
